Skip to main content
SpringerLink
Log in

AE 941 — Neovastat™

  • Section 1: Matrix Metalloprotease Inhibitor
  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. AEterna presents phase I/II clinical results for lung cancer using AE-941/Neovastat at ESMO. Canada Newswire [online].: [2 pages], 1998 Nov 10. Available from: URL: http://www.newspage.com

    Google Scholar 

  2. AEterna Laboratories Inc. AEterna/clinical results from phase I of the prostate and lung cancer study confirm the safety of AE-941/Neovastat. Media Release.: [2 pages], 1998 Aug 21

    Google Scholar 

  3. Dupont E, Alaoui-Jamali M, Wang T, et al. Angiostatic and antitumoral activity of AE-941 (NeovastatRm), a molecular fraction derived from shark cartilage. 88th Annual Meeting of the American Association for Cancer Research; 197 Apr 12–16; San Diego. Philadelphia: American Association for Cancer Research, 1997: 227

    Google Scholar 

  4. Aeterna/positive combination of chemotherapy and Neovastat. Canada Newswire [online].: [2 pages], 1997 Sep 29. Available from: URL: http://www.newspage.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

AE 941 — Neovastat™. Drugs R&D 1, 135–136 (1999). https://doi.org/10.2165/00126839-199901020-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199901020-00003

Keywords

Search

Navigation